No material Eli Lilly-specific corporate disclosures appeared in briefings covering the period to mid-July 2026 [Brief - 2026-07-11]. The broader US macro environment during this period was shaped by a June nonfarm payrolls reading of 57,000, materially below consensus estimates of 110,000–115,000 [Brief - 2026-07-03]. US equity markets recorded their strongest quarterly performance in six years as of 30 June 2026, partly influenced by a US Supreme Court ruling that reversed Trump administration tariff policies [Brief - 2026-06-30]. Separately, the death of Iranian Supreme Leader Ayatollah Ali Khamenei introduced geopolitical uncertainty during the same period [Brief - 2026-07-05].
As of the quarter ending 31 March 2026, Eli Lilly reported trailing twelve-month revenue of $72.25 billion, reflecting year-over-year revenue growth of 55.5% and EPS growth of 169.9% [SEC 10-Q - LLY - 2026-03-31]. Net income on a TTM basis stood at $25.28 billion, with a net margin of approximately 35.0% [SEC 10-Q - LLY - 2026-03-31]. The company held $5.28 billion in cash against total debt of $43.37 billion, yielding a net debt position of approximately $38.09 billion [SEC 10-Q - LLY - 2026-03-31]. The reported P/E ratio stood at 41.89 as of the same date [SEC 10-Q - LLY - 2026-03-31].
Institutional ownership data from the most recent 13F filings showed divergent positioning among major managers. Citadel reduced its LLY position by 29% and Millennium reduced its position by 6.5% [SEC 13F - Citadel - Q1 2026] [SEC 13F - Millennium - Q1 2026]. Conversely, AQR Capital added 69% to its existing position, and ARK Invest opened a new position in the company during the same reporting period [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - ARK Invest - Q1 2026]. These divergent moves across prominent institutional managers constituted the primary trigger for this report.
The prevailing macro backdrop as of the report generation date showed the US 10-year Treasury yield at 4.57% and the 2-year yield at 4.16%, representing a normal yield curve configuration with a spread of approximately 41 basis points [FRED DGS10] [FRED DGS2]. The June payrolls miss of 57,000 against consensus expectations of 110,000–115,000 renewed debate regarding the trajectory of Federal Reserve policy, a factor with broad relevance across large-cap equities including pharmaceutical names [Brief - 2026-07-03].